Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
Clinical trial NCT03185494 · UNKNOWN
Trial details
- NCT number
- NCT03185494
- Sponsor
- Chinese PLA General Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-01
- Primary completion
- 2019-08-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.